



Company Overview

Sonoma Pharmaceuticals is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The company's products, which are sold throughout the world, have improved outcomes for more than ten million patients globally by reducing infection, itch, pain, scarring and harmful inflammatory responses. Sonoma's headquarters are in Petaluma, California, with manufacturing operations in both the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands.

Sonoma Pharmaceuticals Announces Management Changes

Dec 14 2018, 5:30 PM EST

Sonoma Pharmaceuticals Announces Pricing of Public Offering of Units

Nov 17 2018, 11:01 AM EST

Sonoma Pharmaceuticals Reports Record Revenue in Second Quarter FY 2019

Nov 8 2018, 4:03 PM EST

Stock Overview

Symbol	SNOA
Exchange	Nasdaq
Market Cap	8.93m
Last Price	\$0.8005
52-Week	\$0.6399 - \$4.80

Investor Relations

T: 707-559-7380
ir@sonomapharma.com

02/15/2019 04:00 PM EST

Management Team

"Bubba" Sandford

CEO/CFO

Marc Umscheid

Chief Operating Officer

Bruce Thornton

Executive Vice President

Robert Northey Ph.D

Director of Research and Development

Sonoma Pharmaceuticals, Inc.

1129 North McDowell Blvd.
Petaluma, CA 94954

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.